BioCentury | Dec 17, 2020
Product Development

Two non-amyloid therapies for Alzheimer’s advance to late-stage trials

...lysine gingipain, a protease produced by the periodontitis-causing bacteria.Cortexyme’s...
BioCentury | Dec 5, 2020
Product Development

Cortexyme’s Alzheimer’s therapy passes futility analysis, but investors aren’t impressed

...a futility analysis that would have been difficult to fail By selina koch, executive editor Cortexyme’s...
...agent failed to demonstrate overwhelming efficacy (p=0.005), a second goal of the interim analysis.Shares of Cortexyme Inc....
...periodontitis-causing bacteria, bringing a fresh approach to a disease in serious need of new ideas. Selina Koch COR388 Cortexyme Inc. Neurology Alzheimer's...
BioCentury | May 2, 2020
Management Tracks

Catalent’s Boerman becomes president of cell and gene therapy; plus Stanford, Intellia, Cortexyme, CZ Biohub, Grail and more

...Lebwohl as EVP and CMO. He was CMO of Semma Therapeutics Inc. Neurodegenerative diseases company Cortexyme Inc....
...He was CFO of Spring Bank Pharmaceuticals Inc. (NASDAQ:SBPH). Robin Sawka, BioCentury Staff Catalent Inc. Stanford University Intellia Therapeutics Inc. Cortexyme Inc. Chan...
BioCentury | Sep 13, 2019
Company News

Management tracks: Orchard, Black Diamond, ALK-Abelló, Menarini, Imvax, Rallybio, Milestone, MaaT and more

...helped the company raise $156 million across three financings including an IPO on NASDAQ (see “Cortexyme’s...
BioCentury | Aug 22, 2019
Tools & Techniques

Digital makes its mark on cognition

...as exploratory endpoints in larger trials that could support subsequent use as a primary endpoint. Cortexyme Inc....
...secondary endpoints are physician-administered subjective tests of cognition. The partners first used Speech Assessment in Cortexyme’s...
...Assessment could be used as a primary endpoint. That timeline includes the readout from the Cortexyme...
BioCentury | Jul 13, 2019
Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

...their IPO, with most also having substantial insider support in the IPO itself. For example, Cortexyme Inc....
...8% in May, Cortexyme had a massive first day pop, jumping $15.89 (93%) to $32.89. Cortexyme...
...NASDAQ:IDYA) 5/22/19 $57.5 $202.3 $201.5 0% Applied Therapeutics Inc. (NASDAQ:APLT) 5/13/19 $40.0 $170.5 $140.5 -18% Cortexyme Inc....
BioCentury | Jun 28, 2019
Financial News

IPO window wide open: BridgeBio leads new listings with year’s largest

...increased their share price, with two other companies -- Turning Point Therapeutics Inc. (NASDAQ:TPTX) and Cortexyme Inc....
BioCentury | May 23, 2019
Financial News

How Bicycle, Ideaya fared in debuts as they join 2019’s growing IPO class

...volatile trading in May as trade tensions between the U.S. and China have escalated (see "Cortexyme's...
BioCentury | May 13, 2019
Financial News

May 13 Financial Quick Takes: Biotech trio update IPO plans, plus Vedanta, TreeFrog

...a week that had five biotechs go public, four of which priced within range (see “Cortexyme’s...
BioCentury | May 9, 2019
Finance

Cortexyme’s first-day pop leads IPO quartet amid choppy market

...will be closely watched by the bolus of companies in the IPO queue. CNS company Cortexyme Inc....
...of Thursday’s session, while metabolic company Axcella Health Inc. (NASDAQ:AXLA) priced at the bottom end. Cortexyme...
...Industrial Average was off 2.1% during that period, and the NASDAQ Composite was off 3%. Cortexyme...
Items per page:
1 - 10 of 30
BioCentury | Dec 17, 2020
Product Development

Two non-amyloid therapies for Alzheimer’s advance to late-stage trials

...lysine gingipain, a protease produced by the periodontitis-causing bacteria.Cortexyme’s...
BioCentury | Dec 5, 2020
Product Development

Cortexyme’s Alzheimer’s therapy passes futility analysis, but investors aren’t impressed

...a futility analysis that would have been difficult to fail By selina koch, executive editor Cortexyme’s...
...agent failed to demonstrate overwhelming efficacy (p=0.005), a second goal of the interim analysis.Shares of Cortexyme Inc....
...periodontitis-causing bacteria, bringing a fresh approach to a disease in serious need of new ideas. Selina Koch COR388 Cortexyme Inc. Neurology Alzheimer's...
BioCentury | May 2, 2020
Management Tracks

Catalent’s Boerman becomes president of cell and gene therapy; plus Stanford, Intellia, Cortexyme, CZ Biohub, Grail and more

...Lebwohl as EVP and CMO. He was CMO of Semma Therapeutics Inc. Neurodegenerative diseases company Cortexyme Inc....
...He was CFO of Spring Bank Pharmaceuticals Inc. (NASDAQ:SBPH). Robin Sawka, BioCentury Staff Catalent Inc. Stanford University Intellia Therapeutics Inc. Cortexyme Inc. Chan...
BioCentury | Sep 13, 2019
Company News

Management tracks: Orchard, Black Diamond, ALK-Abelló, Menarini, Imvax, Rallybio, Milestone, MaaT and more

...helped the company raise $156 million across three financings including an IPO on NASDAQ (see “Cortexyme’s...
BioCentury | Aug 22, 2019
Tools & Techniques

Digital makes its mark on cognition

...as exploratory endpoints in larger trials that could support subsequent use as a primary endpoint. Cortexyme Inc....
...secondary endpoints are physician-administered subjective tests of cognition. The partners first used Speech Assessment in Cortexyme’s...
...Assessment could be used as a primary endpoint. That timeline includes the readout from the Cortexyme...
BioCentury | Jul 13, 2019
Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

...their IPO, with most also having substantial insider support in the IPO itself. For example, Cortexyme Inc....
...8% in May, Cortexyme had a massive first day pop, jumping $15.89 (93%) to $32.89. Cortexyme...
...NASDAQ:IDYA) 5/22/19 $57.5 $202.3 $201.5 0% Applied Therapeutics Inc. (NASDAQ:APLT) 5/13/19 $40.0 $170.5 $140.5 -18% Cortexyme Inc....
BioCentury | Jun 28, 2019
Financial News

IPO window wide open: BridgeBio leads new listings with year’s largest

...increased their share price, with two other companies -- Turning Point Therapeutics Inc. (NASDAQ:TPTX) and Cortexyme Inc....
BioCentury | May 23, 2019
Financial News

How Bicycle, Ideaya fared in debuts as they join 2019’s growing IPO class

...volatile trading in May as trade tensions between the U.S. and China have escalated (see "Cortexyme's...
BioCentury | May 13, 2019
Financial News

May 13 Financial Quick Takes: Biotech trio update IPO plans, plus Vedanta, TreeFrog

...a week that had five biotechs go public, four of which priced within range (see “Cortexyme’s...
BioCentury | May 9, 2019
Finance

Cortexyme’s first-day pop leads IPO quartet amid choppy market

...will be closely watched by the bolus of companies in the IPO queue. CNS company Cortexyme Inc....
...of Thursday’s session, while metabolic company Axcella Health Inc. (NASDAQ:AXLA) priced at the bottom end. Cortexyme...
...Industrial Average was off 2.1% during that period, and the NASDAQ Composite was off 3%. Cortexyme...
Items per page:
1 - 10 of 30